Displaying 421 - 440 of 1638
Thomas Jefferson University, et al.
The Federal Trade Commission has issued an administrative complaint and authorized a federal court action to block the proposed merger of Jefferson Health and Albert Einstein Healthcare Network, two leading providers of inpatient general acute care hospital services and inpatient acute rehabilitation services in both Philadelphia County and Montgomery County, Pennsylvania. The proposed merger would eliminate the robust competition between Jefferson and Einstein for inclusion in health insurance companies’ hospital networks to the detriment of patients. The Commission vote to issue the administrative complaint and to authorize staff to seek a temporary restraining order and preliminary injunction was 4-0-1, with Chairman Joseph J. Simons recused. The administrative trial is scheduled to begin on Sept. 1, 2020.
Zero Gravity Skin (Perfectio medical devices)
FTC Requires Veterinary Service Providers Compassion First and National Veterinary Associates to Divest Assets in Three Local Markets
FTC Acts to Stop Two Companies from Making Unproven Bone and Joint Claims
FTC, FDA Sign Joint Statement Promoting Competition in Markets for Biologics
Joint FDA-FTC Statement Regarding Collaboration to Advance Competition in the Biologic Marketplace
Statement of the FTC Chairman Regarding Announcement that Aveanna Healthcare and Maxim Healthcare Services have Terminated Their Acquisition Agreement
FTC and NY Attorney General Charge Vyera Pharmaceuticals, Martin Shkreli, and Other Defendants with Anticompetitive Scheme to Protect a List-Price Increase of More Than 4,000 Percent for Life-Saving Drug Daraprim
FTC Comments to State Legislatures in Kansas and Ohio Encourage Granting Advanced Practice Registered Nurses Full Practice Authority
FTC Staff Comment to the Kansas House of Representatives Concerning Kansas House Bill 2412
FTC Staff Comment to the Ohio House of Representatives Concerning Ohio House Bill 177
Illumina Inc./Pacific Biosciences of California, Inc., In the Matter of
The Federal Trade Commission authorized an action to block Illumina Inc.’s proposed $1.2 billion acquisition of Pacific Biosciences of California, alleging in an administrative complaint that Illumina is seeking to unlawfully maintain its monopoly in the U.S. market for next-generation DNA sequencing systems by extinguishing PacBio as a nascent competitive threat. The Commission vote to issue the administrative complaint and to authorize staff to seek a temporary restraining order and preliminary injunction was 5-0. On Jan. 2, 2020, the parties abandoned the transaction.
Statement of Gail Levine, Deputy Director of FTC Bureau of Competition, Regarding the Announcement that Illumina Inc. has Abandoned Its Proposed Acquisition of Pacific Biosciences of California
FTC Challenges Illumina’s Proposed Acquisition of PacBio
Statement of the Federal Trade Commission in the matter of Roche Holding/Spark Therapeutics
Displaying 421 - 440 of 1638